Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPH966 for Prevention of GVHD After Allogeneic HCT
NCT03986086Phase 2Withdrawn
- Start
- Sep 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alvelestat in graft-versus-host disease (GVHD). Planned start Sep 2021; status: withdrawn.
02
Drugs
alvelestat
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03986086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03986086.